Next-generation vaccine ideas to prevent C. difficile illness
Official title: Enhancing C. difficile vaccination in the context of TcdB-mediated immunosuppression.
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11377662 · Data updated 2026-11-12
A new C. difficile vaccine approach is being tested to protect people from serious stomach infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | July 25, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $337,404 |
| NIH project number | 5U19AI174994-04 |
| Project ID | NIH-11377662 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for C. difficile infection, such as those with recent antibiotic exposure or healthcare-associated risk factors, once a vaccine becomes available.
✕Less likely to help
People without exposure to C. difficile risk factors or those not eligible for vaccine trials would not directly benefit.
What this research studies
This project focuses on creating a safer, more effective vaccine against C. difficile by improving a mutant version of the TcdB toxin and comparing it to a toxoid. The work includes optimizing vaccine formulations, adding a polysaccharide component, and testing protection in mouse and hamster infection models. Researchers will also examine how C. difficile may affect immune cells that are important for lasting protection. The goal is to identify vaccine candidates with strong safety profiles and durable immune responses for future clinical development.
Why it matters
Potential benefit: If successful, the research could lead to a more effective vaccine that prevents C. difficile illness and reduces related deaths.
How similar studies have gone: Prior vaccine research in this area has identified promising toxin-based approaches, with ongoing work to improve safety and efficacy.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Ballard, Jimmy D. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Ballard, Jimmy D.
Related research
Other NIH-funded projects on the same topics.
-
RSV vaccine in people with immune suppression: how antibodies form and work
This grant studies how vaccines for RSV work in people with weakened immune systems and aims to improve how vaccines protect them.
-
A New Vaccine for C. difficile Infection
This project aims to create a better vaccine to protect people from serious C. difficile infections.
-
Improving vaccines to prevent C. difficile infections.
This study is working on a new vaccine to help protect people from Clostridioides difficile infections, which can cause serious stomach problems, by using a safe version of a toxin to boost the immune system, and it will also look at how this bacteria might make vaccines less effective.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.